IIQ

INOVIQ LTD FPO [IIQ]
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases. The company was formerly known as BARD1 Life Sciences Limited and changed its name to INOVIQ Ltd in December 2021. INOVIQ Ltd was founded in 2016 and is headquartered in Notting Hill, Australia.
Healthcare · ASX Small Cap
$0.1850 +5.7%

Updated 3 Sep 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-03-02
Get alerts when IIQ triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track IIQ — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Above-average volume (1.8x) on a green day — buyers stepping up
  • Adequate cash runway (6 quarters)
  • Moderate P/S ratio (12.1x)
  • Moderate revenue growth (+11%)
  • EPS estimates revised upward (+10pts)
  • Near 52-week low (6% of range)
  • Small-cap ($20-100M)
  • New substantial holder(s) (1)
  • Sentiment is mixed — no strong consensus either way
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 41% over the past year
  • The bigger volume days are the down days — volume-weighted momentum is negative (-6.12%/day)
Ask Scout AI about IIQ
"What's driving IIQ today?" "How does IIQ compare to peers?" "Key risks for IIQ?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Appendix 4G and Corporate Governance Statement
NONE Appendix 4E and Preliminary Financial Report
NONE Change of Director's Interest Notice
HIGH Becoming a substantial holder

Recent ASX Announcements

2026-08-26 Appendix 4G and Corporate Governance Statement
2026-08-26 Appendix 4E and Preliminary Financial Report PRICE SENSITIVE
2026-08-06 Becoming a substantial holder
2026-07-15 Change of Director's Interest Notice
2026-07-13 EXO-OC Study Outcome Investor Webinar Presentation PRICE SENSITIVE

Key Metrics

$26.7M
Market Cap
111K
Avg Volume
1.8x
Vol Ratio
$0.17 — $0.56
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-42.2%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 82%
LLeader vs LaggardlaggardRS: -21
IInstitutional SponsorshipweakInst: 7%
MMarket DirectionneutralNeutral

Sector: Healthcare

113 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
REG -27.0%CAN +25.0%BIT -20.0%MEM +20.0%CMP -14.6%
Compare:IIQ vs REGIIQ vs CANIIQ vs BIT
Scout Pro — Deeper Analysis for IIQ
Try Pro free for 30 days
Share this analysis

Track IIQ and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required